121 related articles for article (PubMed ID: 2143744)
21. Idiopathic myelofibrosis serum induces increased DNA synthesis in BALB/c 3T3 cells.
Polato G; Pietrogrande F; Caenazzo A; Piva E; Burlina A; Girolami A
Folia Haematol Int Mag Klin Morphol Blutforsch; 1990; 117(3):469-73. PubMed ID: 1703119
[TBL] [Abstract][Full Text] [Related]
22. Defective platelet aggregation and increased platelet turnover in patients with myelofibrosis and other myeloproliferative diseases.
Cunietti E; Gandini R; Mascaro G; Ferrari M; Pappalepore V; Scapellato L
Scand J Haematol; 1981 Apr; 26(4):339-44. PubMed ID: 6461058
[TBL] [Abstract][Full Text] [Related]
23. Platelet-derived growth factor receptor β (PDGFRβ) immunohistochemistry highlights activated bone marrow stroma and is potentially predictive for fibrosis progression in prefibrotic myeloproliferative neoplasia.
Méhes G; Tzankov A; Hebeda K; Anagnostopoulos I; Krenács L; Bedekovics J
Histopathology; 2015 Nov; 67(5):617-24. PubMed ID: 25825163
[TBL] [Abstract][Full Text] [Related]
24. Megakaryocytes and myelofibrosis in gray platelet syndrome.
Caen JP; Deschamps JF; Bodevin E; Bryckaert MC; Dupuy E; Wasteson A
Nouv Rev Fr Hematol (1978); 1987; 29(2):109-14. PubMed ID: 3615193
[TBL] [Abstract][Full Text] [Related]
25. Quantitative analysis of growth factor production in the mechanism of fibrosis in agnogenic myeloid metaplasia.
Wang JC; Chang TH; Goldberg A; Novetsky AD; Lichter S; Lipton J
Exp Hematol; 2006 Dec; 34(12):1617-23. PubMed ID: 17157157
[TBL] [Abstract][Full Text] [Related]
26. Platelet PDGF and TGF-β Levels in Myeloproliferative Disorders.
Martyré MC
Leuk Lymphoma; 1991; 6(1):1-6. PubMed ID: 27457569
[TBL] [Abstract][Full Text] [Related]
27. Mixed myelodysplastic syndrome and myeloproliferative disorder with bone marrow and pulmonary fibrosis: the role of megakaryocytes.
Rosenstingl S; Brouland JP; Zini JM; Tobelem G; Dupuy E
Acta Haematol; 2003; 109(3):145-9. PubMed ID: 12714825
[TBL] [Abstract][Full Text] [Related]
28. Quantitation of RNA-dependent platelet DNA polymerase in patients with myeloproliferative disorders.
Strayer DR; Brodsky I; Caranfa MJ; Gillespie DH
Br J Haematol; 1982 Mar; 50(3):521-30. PubMed ID: 6175335
[TBL] [Abstract][Full Text] [Related]
29. [Mechanism of myelofibrosis in chronic myeloproliferative disorders].
Nagao T; Yonekura S
Rinsho Ketsueki; 1988 Jul; 29(7):983-8. PubMed ID: 2846914
[No Abstract] [Full Text] [Related]
30. Platelet 5-hydroxytryptamine transport and storage in myeloproliferative disorders.
Cortellazzo S; Viero P; Buczko W; Barbui T; de Gaetano G
Scand J Haematol; 1985 Feb; 34(2):146-51. PubMed ID: 3856312
[TBL] [Abstract][Full Text] [Related]
31. Investigation of calmodulin and basic fibroblast growth factor (bFGF) in idiopathic myelofibrosis: evidence for a role of extracellular calmodulin in fibroblast proliferation.
Dalley A; Smith JM; Reilly JT; Neil SM
Br J Haematol; 1996 Jun; 93(4):856-62. PubMed ID: 8703817
[TBL] [Abstract][Full Text] [Related]
32. Platelet-derived growth factor release and antiplatelet treatment with low-dose acetylsalicylic acid.
Vissinger H; Husted SE; Kristensen SD; Nielsen HK
Angiology; 1993 Aug; 44(8):633-8. PubMed ID: 8342880
[TBL] [Abstract][Full Text] [Related]
33. Myelofibrosis in myeloproliferative disorders.
Srinivasan U; Talvalkar GV; Advani SH
Indian J Cancer; 1978 Sep; 15(3):37-43. PubMed ID: 294411
[No Abstract] [Full Text] [Related]
34. Platelet-derived growth factor concentrations in platelet-poor plasma and urine from patients with myeloproliferative disorders.
Gersuk GM; Carmel R; Pattengale PK
Blood; 1989 Nov; 74(7):2330-4. PubMed ID: 2804368
[TBL] [Abstract][Full Text] [Related]
35. Bone marrow lymphoid nodules in myeloproliferative disorders: association with the nonmyelosclerotic phases of idiopathic myelofibrosis and immunological significance.
Cervantes F; Pereira A; Marti JM; Feliu E; Rozman C
Br J Haematol; 1988 Nov; 70(3):279-82. PubMed ID: 3207625
[TBL] [Abstract][Full Text] [Related]
36. Defective platelet beta-N-acetyl hexosaminidase content and release in chronic myeloproliferative disorders.
Emiliani C; Ciferri S; Mencarelli S; Mezzasoma AM; Momi S; Orlacchio A; Gresele P
Platelets; 2006 Feb; 17(1):20-9. PubMed ID: 16308183
[TBL] [Abstract][Full Text] [Related]
37. Increased Dkk3 protein expression in platelets and megakaryocytes of patients with myeloproliferative neoplasms.
Medinger M; Tzankov A; Kern J; Pircher A; Hermann M; Ott HW; Gastl G; Untergasser G; Gunsilius E
Thromb Haemost; 2011 Jan; 105(1):72-80. PubMed ID: 20978717
[TBL] [Abstract][Full Text] [Related]
38. Aberrant expression of transforming growth factor beta-1 (TGF beta-1) per se does not discriminate fibrotic from non-fibrotic chronic myeloproliferative disorders.
Bock O; Loch G; Schade U; von Wasielewski R; Schlué J; Kreipe H
J Pathol; 2005 Apr; 205(5):548-57. PubMed ID: 15726648
[TBL] [Abstract][Full Text] [Related]
39. Decreased platelet mitogenic activity in patients with diabetes mellitus.
Caenazzo A; Pietrogrande F; Polato G; Piva E; Sartori D; Girolami A
Haematologia (Budap); 1991; 24(4):241-7. PubMed ID: 1844233
[TBL] [Abstract][Full Text] [Related]
40. Substance p-fibronectin-cytokine interactions in myeloproliferative disorders with bone marrow fibrosis.
Rameshwar P; Oh HS; Yook C; Gascon P; Chang VT
Acta Haematol; 2003; 109(1):1-10. PubMed ID: 12486316
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
